GI Tract
  • Does Mucosal Inflammation Cause Diverticulosis?

Does Mucosal Inflammation Cause Diverticulosis?

Despite limited evidence that a chronic state of low-grade mucosal inflammation contributes to development of diverticulosis, a prospective study published in the June issue of Clinical Gastroenterology and Hepatology found no correlation of the disease with mucosal inflammation, upregulated immune markers, or gastrointestinal symptoms. Colonic diverticulosis (outpouchings from the colonic lumen) is

Read more

Gastroenterology Special Issue on Endoscopy

A special issue of Gastroenterology, Advances in Endoscopic Therapy, presents the latest advances in gastrointestinal endoscopy, including endoscopic images and videos. In their introductory article, Jacques J. Bergman and Patrick S. Yachimski explain that endoscopy is central to gastroenterology clinical practice and research, allowing examination of healthy and diseased tissue from the organ level, to the

Read more
  • What Changes Occur in the Esophageal Epithelial Barrier During Disease Development?

What Changes Occur in the Esophageal Epithelial Barrier During Disease Development?

A review article in the May issue of Clinical Gastroenterology and Hepatology discusses esophageal epithelial barrier structure and function, new and old techniques for studying this barrier, and changes that occur during development of esophageal diseases. To identify mechanisms of diseases associated with barrier dysfunction, such as gastroesophageal reflux disease (GERD), eosinophilic esophagitis,

Read more
  • What Are the Best Endpoints for Trials of Agents for Ulcerative Colitis?

What Are the Best Endpoints for Trials of Agents for Ulcerative Colitis?

Despite advances in methods of clinical trials for ulcerative colitis (UC), there is still a large amount of variation in endpoints, even in definitions of response and remission, reseachers found in a systematic review published in the May issue of Clinical Gastroenterology and Hepatology. The authors conclude that we need a

Read more

A Parasitic Infection From Sashimi

Researchers report a case of anisakiasis, caused by nematodes of the genus Anisakis—a parasite transmitted to humans through raw seafood such as sushi and sashimi. In the May issue of Gastroenterology, Kaori Ikegami et al describe the case of a 47-year-old man who arrived at the emergency department with severe epigastric pain.

Read more
  • What is the Best Way to Assess Treatment Response in Patients With Achalasia?

What is the Best Way to Assess Treatment Response in Patients With Achalasia?

A more accurate method to evaluate outcomes of treatment for achalasia is described in the May issue of Clinical Gastroenterology and Hepatology. The method identifies patients with good outcomes with higher levels of sensitivity (same specificity) than timed-barium esophagrams or impedance-manometry bolus transit assessments alone. Achalasia is an esophageal motor disorder

Read more
  • Does Drinking Coffee Increase Survival of Patients With Colorectal Cancer?

Does Drinking Coffee Increase Survival of Patients With Colorectal Cancer?

Drinking 2 or more cups of coffee per day after a diagnosis of stage I to III colorectal cancer (CRC) reduces risk of CRC-specific and all-cause mortality, researchers report in the March issue of Gastroenterology. Patients who maintain a high level of coffee consumption before and after diagnosis have even better odds for survival.

Read more
  • Surgical vs Endoscopic Treatment of T1 Esophageal Adenocarcinoma?

Surgical vs Endoscopic Treatment of T1 Esophageal Adenocarcinoma?

Endoscopic therapy of T1a esophageal adenocarcinoma (EAC) yields more quality-adjusted life years (QALYs) and is more cost effective than esophagectomy, shows a Markov model analysis published in the March issue of Clinical Gastroenterology and Hepatology. However, therapy for T1b EAC should be selected based on patients’ age and comorbidities. Although EAC has

Read more
  • What Happens When Patients With Crohn’s Disease in Remission Stop Taking Infliximab?

What Happens When Patients With Crohn’s Disease in Remission Stop Taking Infliximab?

When patients with Crohn’s disease in sustained remission stopped taking infliximab for a median 7 years, almost one fifth did not require retreatment or have a major complication, researchers report in the February issue of Clinical Gastroenterology and Hepatology. Fewer than one fifth of patients required surgery or developed a complex perianal fistula. Increasing numbers of patients

Read more
  • Model: Microfabricated Crypt Scaffolds for Studying Human Colon Stem Cells

Model: Microfabricated Crypt Scaffolds for Studying Human Colon Stem Cells

Researchers created an in vitro human colon crypt array that provides an accurate representation of human intestinal crypts, reported in the February issue of Cellular and Molecular Gastroenterology and Hepatology. This system re-creates an intestinal epithelium with a high density of polarized crypts that respond in a physiologic manner to growth factors, metabolites, or

Read more